Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Inventiva S.A. stock logo
IVA
Inventiva
$3.13
-0.2%
$3.29
$1.53
$4.05
$296.01M0.862,986 shs4,664 shs
LifeVantage Co. stock logo
LFVN
LifeVantage
$12.66
-4.1%
$13.55
$5.22
$27.38
$159.36M0.41141,611 shs133,630 shs
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
$1.03
-1.9%
$0.83
$0.49
$4.28
$48.14M0.081.13 million shs242,421 shs
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
$1.89
+7.4%
$1.37
$0.77
$2.07
$188.58M2.341.49 million shs3.09 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Inventiva S.A. stock logo
IVA
Inventiva
-0.16%+0.48%-18.62%+10.04%-15.99%
LifeVantage Co. stock logo
LFVN
LifeVantage
-4.09%-5.45%-0.39%-24.15%+69.48%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-1.90%+25.61%+19.39%-34.39%-28.97%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
+7.39%+15.95%+44.27%+48.82%+32.17%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Inventiva S.A. stock logo
IVA
Inventiva
1.9203 of 5 stars
3.42.00.00.01.81.70.6
LifeVantage Co. stock logo
LFVN
LifeVantage
2.8139 of 5 stars
3.51.01.72.70.01.71.3
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
3.2421 of 5 stars
3.64.00.00.02.33.30.6
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
0.2363 of 5 stars
0.02.00.00.01.90.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Inventiva S.A. stock logo
IVA
Inventiva
2.80
Moderate Buy$10.40232.80% Upside
LifeVantage Co. stock logo
LFVN
LifeVantage
3.00
Buy$30.50140.92% Upside
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
3.29
Buy$9.00773.79% Upside
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest RVPH, LFVN, SLS, and IVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $3.00
4/24/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
4/4/2025
Inventiva S.A. stock logo
IVA
Inventiva
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $9.00
4/1/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $8.00
3/28/2025
Inventiva S.A. stock logo
IVA
Inventiva
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Inventiva S.A. stock logo
IVA
Inventiva
$9.20M32.50N/AN/A($0.67) per share-4.66
LifeVantage Co. stock logo
LFVN
LifeVantage
$222.35M0.72$0.67 per share19.03$2.38 per share5.32
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/AN/AN/AN/A$0.20 per shareN/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
$1M188.58N/AN/A($0.25) per share-7.56
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Inventiva S.A. stock logo
IVA
Inventiva
-$119.51MN/A0.00N/AN/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$2.94M$0.6922.61N/A3.46%34.29%15.04%N/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$39.26M-$0.79N/AN/AN/AN/AN/A-252.53%N/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$37.34M-$0.38N/AN/AN/AN/A-629.46%-178.65%8/12/2025 (Estimated)

Latest RVPH, LFVN, SLS, and IVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$0.21-$0.13+$0.08-$0.13N/AN/A
5/13/2025Q1 2025
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$0.1067-$0.07+$0.0367-$0.07N/AN/A
5/6/2025Q3 2025
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
3/31/2025Q4 2024
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$0.22-$0.15+$0.07-$0.15N/AN/A
3/20/2025Q4 2024
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$0.1067-$0.08+$0.0267-$0.08N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Inventiva S.A. stock logo
IVA
Inventiva
N/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.181.42%N/A26.09%3 Years
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/AN/AN/AN/AN/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
N/AN/AN/AN/AN/A

Latest RVPH, LFVN, SLS, and IVA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
LifeVantage Co. stock logo
LFVN
LifeVantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Inventiva S.A. stock logo
IVA
Inventiva
N/A
0.59
0.59
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A
1.66
1.03
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/A
0.39
0.39
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
N/A
2.26
2.26

Institutional Ownership

CompanyInstitutional Ownership
Inventiva S.A. stock logo
IVA
Inventiva
19.06%
LifeVantage Co. stock logo
LFVN
LifeVantage
35.32%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
63.18%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
17.38%

Insider Ownership

CompanyInsider Ownership
Inventiva S.A. stock logo
IVA
Inventiva
32.00%
LifeVantage Co. stock logo
LFVN
LifeVantage
20.65%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
27.18%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
1.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Inventiva S.A. stock logo
IVA
Inventiva
10095.66 million35.68 millionNot Optionable
LifeVantage Co. stock logo
LFVN
LifeVantage
26012.59 million9.96 millionOptionable
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
546.74 million24.35 millionOptionable
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
1099.78 million69.54 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Inventiva stock logo

Inventiva NASDAQ:IVA

$3.12 -0.01 (-0.16%)
As of 05/23/2025 03:46 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

LifeVantage stock logo

LifeVantage NASDAQ:LFVN

$12.66 -0.54 (-4.09%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$12.70 +0.04 (+0.32%)
As of 05/23/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Reviva Pharmaceuticals stock logo

Reviva Pharmaceuticals NASDAQ:RVPH

$1.03 -0.02 (-1.90%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$1.03 +0.00 (+0.49%)
As of 05/23/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

SELLAS Life Sciences Group stock logo

SELLAS Life Sciences Group NASDAQ:SLS

$1.89 +0.13 (+7.39%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$1.92 +0.03 (+1.32%)
As of 05/23/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.